Bio-Manguinhos in Brazil is poised to supply its mRNA COVID-19 vaccine, while Kenya's Biovax faces salary competition from commercial firms despite a $120 million World Bank loan. The WHO's mRNA technology transfer program aims to establish sustainable vaccine production in low and middle-income countries, with 11 facilities expected by 2030. However, financial challenges persist, requiring an estimated $200 million to enhance manufacturing capabilities and support ongoing research.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
